Close

AbTCR Vector Products

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The remarkable efficacy of anti-CD19 chimeric antigen receptor (CAR) -T cell therapy in patients with leukemia and lymphoma has led to unprecedented response rates, demonstrating the clinical importance of genetically modified T cells as immunotherapy. Despite this clinical success, FDA-approved T-cell therapies are currently limited to B-cell malignancies and challenges remain in managing cytokine-related toxicity.

As a leading cell therapeutics provider, Creative Biolabs has established a novel CellRapeutics™ antibody-TCR (AbTCR) technology platform for the next generation of cell-based therapy. By combining the Fab domain of the antibody with the gamma and delta chains of TCR as effector domains, we demonstrated that AbTCR activates a cytotoxic T cell response similar to conventional CD3ζ-CAR, but with less cytokine release. Therefore, this revolutionary combination product holds huge potential and is expected to become an alternative therapy for cancer treatment.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.